Top Suppliers:I want be here



1312473-63-4

1312473-63-4 structure
1312473-63-4 structure
  • Name: PF-5081090
  • Chemical Name: (2R)-4-[4-(2-fluoro-4-methoxyphenyl)-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide
  • CAS Number: 1312473-63-4
  • Molecular Formula: C18H21FN2O6S
  • Molecular Weight: 412.43300
  • Catalog: Signaling Pathways Anti-infection Bacterial
  • Create Date: 2017-02-19 17:50:46
  • Modify Date: 2025-08-26 20:20:35
  • PF-5081090 (LpxC-4) is a potent LpxC inhibitor, is a rapidly bactericidal with broad-spectrum activity. PF-5081090 serves as a regulator of lipid A biosynthesis in Gram-negative pathogens[1][2].

Name (2R)-4-[4-(2-fluoro-4-methoxyphenyl)-2-oxopyridin-1-yl]-N-hydroxy-2-methyl-2-methylsulfonylbutanamide
Synonyms (|AR)-4-(2-Fluoro-4-methoxyphenyl)-N-hydroxy-|A-methyl-|A-(methylsulfonyl)-2-oxo-1(2H)-pyridinebutanamide
MS 245 oxalate
Description PF-5081090 (LpxC-4) is a potent LpxC inhibitor, is a rapidly bactericidal with broad-spectrum activity. PF-5081090 serves as a regulator of lipid A biosynthesis in Gram-negative pathogens[1][2].
Related Catalog
In Vitro PF-5081090 shows strong potency against a broad spectrum of Gram-negative pathogens with IC50s of 1.1 nM (P. aeruginosa), 0.069 nM (K. pneumonia) and MIC90s of 1 μg/mL (P. aeruginosa, K. pneumoniae), 0.25 μg/mL (E. coli), 0.5 μg/mL (Enterobacter spp), 2 μg/mL (S. maltophilia)[1]. PF-5081090 (0.25 μg/mL; 0-50 h) demonstrates sustained bactericidal activities against P. aeruginosa UC12120 (A), PA-1955 (B), and K. pneumoniae KP-1487[1]. PF-5081090 (32 mg/L) increases antibiotic susceptibility in Acinetobacter baumannii with rifampicin, vancomycin, azithromycin, imipenem and amikacin[2]. PF-5081090 (32 mg/L) inhibits lipid A biosynthesis, and significantly increases cell permeability in A. baumannii[2].
In Vivo PF-5081090 (8.75, 75, 300 mg/kg; s.c.; single dose) exhibits a exposure increasing in linear manner across the dose range in mice, with area under the concentration-time curve (AUC) and maximum concentration of drug in serum (Cmax) increasing with a proportional increase in dose[1]. PF-5081090 shows potent efficacies against sentinel strains of P. aeruginosa and K. pneumonia in CD-1 mice, with effective dose (ED50) ranging from 7.4-55.9 mg/kg (against acute septicemia model), <25 mg/kg (against pneumonia model), and 16.8 mg/kg (against neutropenic thigh model) in mice infected with P. aeruginosa PA-1950[1]. Pharmacokinetics of PF-5081090 in CD-1 micea[1] Dose (mg/kg) Cmax (mg/L) Tmax (h) AUC (h•mg/L) Free AUC (h•mg/L) T1/2 (h) CL (L/h/kg) Vss (L/kg) 18.75 5.02 0.25 5.09 1.58 0.6 3.79 2.20 75 15.50 0.33 17.60 5.46 0.69 4.32 3.30 300 75.40 0.33 76.30 23.70 0.68 3.92 2.53a Following single subcutaneous doses.
References

[1]. Tomaras AP, et al. LpxC inhibitors as new antibacterial agents and tools for studying regulation of lipid A biosynthesis in Gram-negative pathogens. mBio. 2014 Sep 30;5(5):e01551-14.

[2]. García-Quintanilla M, et al. Inhibition of LpxC Increases Antibiotic Susceptibility in Acinetobacter baumannii. Antimicrob Agents Chemother. 2016 Jul 22;60(8):5076-9.

Molecular Formula C18H21FN2O6S
Molecular Weight 412.43300
Exact Mass 412.11000
PSA 126.57000
LogP 3.28290
RIDADR NONH for all modes of transport
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.